This is the standing evidence sheet for Cormedix (CRMD): the yardsticks BullScope computes from official SEC filings and market prices. It refreshes whenever a new edition of our research is published, and it is impersonal by design, every reader sees the same page. Nothing here is investment advice; it is the evidence, organized.
The price tag: what buyers pay per dollar of profit
Today the market pays about $2.4 for each $1 of Cormedix’s annual profit (a price-to-earnings ratio of 2.4, computed on FY2025 diluted EPS of $2.04 as filed in the annual report — methodology). Across years in which positive earnings were reported, the median P/E was 3.8 (years with negative earnings were excluded; BullScope methodology); the current reading sits near the low end of that historical range. Whether that gap reflects a durable discount or a deterioration in the underlying business is a question the evidence elsewhere on this sheet addresses.
The tape: what the stock itself has done
- Last price: $4.66 (end-of-day market data as of the edition date · methodology) · 63% below its 52-week high
- Past 6 months: -38.3% · past 12 months: -59.2%
- Day-to-day temperament: jumpy (annualized volatility 64%)
The filed record: straight from the annual reports
| Fiscal year | Revenue | Growth | Operating margin | EPS |
|---|---|---|---|---|
| FY2021 | $0.0B | -20.2% | -15417.5% | $None |
| FY2022 | $0.0B | -65.7% | -46819.9% | $-0.74 |
| FY2023 | $0.0B | +0.0% | -74849.8% | $-0.91 |
| FY2024 | $0.0B | +66363.1% | -51.4% | $-0.3 |
| FY2025 | $0.3B | +617.0% | 48.2% | $2.04 |
The road ahead: filed results vs published expectations
| FY2023A | FY2024A | FY2025A | FY2026E | FY2027E | |
|---|---|---|---|---|---|
| Net sales ($B) | 0.00 | 0.02 | 0.30 | 0.38 to 0.52 | 0.45 to 0.72 |
| Net sales growth (%) | NM | +NM | +1583% | 27 to 73 | 18 to 38 |
| Operating margin (%) | -NM | -NM | 48.2% | 22 to 35 | 20 to 38 |
| Diluted EPS ($) | -0.91 | -0.30 | 2.04 | 1.44-3.14 | 1.19-4.39 |
Columns marked A are actual filed results; E columns are the published consensus ranges the current price is being weighed against.
The four gauges: from the latest edition
BullScope coverage of Cormedix
- CorMedix’s Reimbursement Cliff Meets a $145 Million Bet: What the Call Said, What the Filing Confirmed
- CorMedix’s Scorecard: What Management Said, What the Filings Show, and Where the Story Gets Complicated
- CorMedix: The Company That Went From Zero to Profitable, and the Filing That Could Change the Equation Again
Read the full report on Cormedix in the BullScope Terminal → It opens with this company loaded.
Edition date: 2026-11-16. This page updates when a new edition is published. Sources: SEC EDGAR filings, Nasdaq prices; computed by BullScope’s published methodology.








